Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Zacks Releases Four Powerful ''Buy'' Stocks: Amedisys, Cash America International, Laclede Group and Bucyrus

Wed. October 08, 2008; Posted: 07:33 PM
Stocks RSS
CHICAGO, Oct 08, 2008 (BUSINESS WIRE) -- LG | Quote | Chart | News | PowerRating -- Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value.

The four highlighted picks are: Amedisys, Inc. (Nasdaq: AMED), Cash America International (NYSE: CSH), Laclede Group, Inc. (NYSE: LG | Quote | Chart | News | PowerRating) and Bucyrus (Nasdaq: BUCY).

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free at http://at.zacks.com/?id=88

Zacks #1 Rank Stocks have nearly tripled the S&P 500 since 1988, producing an average annual return of +30%. Performance has been notable even during volatile and down times. For example, during the last bear market, 2000-2002, the market tumbled -37.6% -- but Zacks #1 Rank stocks gained +43.8%.

Here is a summary of today's selected stocks that are now highly rated by Zacks:

Aggressive Growth -- Amedisys, Inc. (Nasdaq: AMED)

Amedisys continues to aggressively pursue acquisitions nation-wide. The company is coming off of a record quarter and earnings estimates are rising heading into its next earnings announcement on Oct 28.

Zacks Guide to Aggressive Growth Investing (free!): http://at.zacks.com/?id=4309

Growth & Income -- Cash America International (NYSE: CSH)

Cash America International recently announced that it will acquire an 80% ownership interest in a 100 store chain of pawnshops in Mexico. CSH noted that this transaction would allow it to acquire what is believed to be the second largest privately owned pawn chain in Mexico through a majority purchase of the parent company which owns and operates the business.

Zacks Guide to Growth & Income Investing (free!): http://at.zacks.com/?id=4310

Momentum -- Laclede Group, Inc. (NYSE: LG)

Laclede Group just posted a new 52-week and all-time high, as the company continues to benefit from higher energy prices. Analyst estimates have continued to rise over the last several months.

Zacks Guide to Momentum Investing (free!): http://at.zacks.com/?id=4311

Value -- Bucyrus (Nasdaq: BUCY)

Bucyrus has seen its stock pummeled in the commodities sell-off and market rout. Shares tumbled from a high on June 17 of $79.50 to $28.77 on Oct 6. The markets are acting as if all worldwide mining will grind to a halt.

Zacks Guide to Value Investing (free!): http://at.zacks.com/?id=4312

How to Regularly Access Picks from the Zacks Rank Discovery for Free: http://at.zacks.com/?id=88

Underlying the four free stock picks is a simple truth that first appeared in a Financial Analysts Journal article published in 1979. Leonard Zacks, a Ph.D. in Mathematics from M.I.T. found that "earnings estimate revisions are the most powerful force impacting stock prices." Zacks #1 Rank is awarded to a stock when analysts sharply upgrade their estimates of what the company will earn.

Today, Zacks is promoting its stock recommendations by offering four daily picks free to those who register at http://at.zacks.com/?id=88

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.

Then, when changes are discovered, they're applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock-picking system continues to outperform the market by a nearly 3-to-1 margin.

More Free Stock Picks

Each weekday, new Zacks #1 Rank or Zacks #2 Rank stock picks are released on the free email newsletter, Profit from the Pros. Investors are invited to register for their free subscription at http://at.zacks.com/?id=91

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

SOURCE: Zacks.com

Zacks.com Aggressive Growth Stocks: Contact: Bill Wilton Phone: 312-265-9277 or Growth & Income Stocks: Contact: Alex Kolb Phone: 312-265-9149 or Momentum Stocks: Contact: Michael Vodicka Phone: 312-265-9226 or Value Stocks: Contact: Tracey Ryniec Phone: 312-265-9232 Email: pr@zacks.com Visit: www.zacks.com

For full details on Amedisys Inc (AMED) click here. Amedisys Inc (AMED) has Short Term PowerRatings of 3. Details on Amedisys Inc (AMED) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [AMED]
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2008 The Connors Group, Inc.